Becker's Healthcare September 26, 2024
Alexandra Murphy

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades, Medscape reported Sept. 20.

Here are five things to know:

  1. KarXT is a coformulation of xanomeline and trospium chloride, designed to selectively activate muscarinic receptors in the brain, unlike traditional antipsychotics that primarily target dopamine receptors.
  2. The safety and effectiveness of the drug was assessed in phase 3 trials, which showed KarXT had a 9.6 point reduction in positive and negative syndrome scale scores compared to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article